Blog

Denis Wirtz: MEK inhibitors have significant off-target toxicity and lack predictive biomarkers

Photo of Denis Wirtz from Johns Hopkins Whiting School of Engineering

Jul 30, 2024, 13:29

Denis Wirtz: MEK inhibitors have significant off-target toxicity and lack predictive biomarkers

Denis Wirtz, Vice Provost of Research at Johns Hopkins University, shared on X about recent paper by Paul M. Kuhn et al., titled “Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer” published on MDPI.

Authors: Paul M. Kuhn, Gabriella C. Russo, Ashleigh J. Crawford, Aditya Venkatraman, Nanlan Yang, Bartholomew A. Starich, Zachary Schneiderman, Pei-Hsun Wu, Thi Vo, Denis Wirtz and Efrosini Kokkoli

“MEK inhibitors have significant off-target toxicity and lack predictive biomarkers.

Here, we use a thermosensitive, biodegradable hydrogel with functionalized liposomes for sustained release of MEK inhibitors to E-cad-positive breast tumors.”

Source: Denis Wirtz/X

Aditya Venkatraman Ashleigh J. Crawford Bartholomew A. Starich Breast Cancer cancer Denis Wirtz Efrosini Kokkoli Gabriella C. Russo Johns Hopkins University MEK inhibitors Nanlan Yang OncoDaily Oncology Paul M. Kuhn Pei-Hsun Wu Thi Vo Zachary Schneiderman

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage